Abstract
Spiramycin was less active than erythromycin in vitro against sensitive strains of Staphylococcus aureus, but was as effective against staphylococcal infections in mice when the drugs were administered immediately after infection: spiramycin was relatively more effective in prophylactic experiments when the antibiotics were administered at 4 or at 6 hr before infection. Strains of staphylococci which had been habituated to either spiramycin or erythromycin in vitro showed complete cross-resistance to both antibiotics in vitro, but the majority of a number of erythromycin-resistant strains isolated from patients were sensitive to spiramycin in vitro. Spiramycin was effective against a number of such strains in vivo, but erythromycin had little effect against these infections. Investigation into the distribution of the antibiotics in the serum and tissues of mice showed that spiramycin was maintained in tissues (lung, liver, kidney, spleen and heart) at higher concentrations and for a longer period than erythromycin, although erythromycin was initially present in serum in higher concentrations. It is suggested that the efficacy of spiramycin against experimental infections is due to its persistence in the animal body.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BENAZET F., DUBOST M. Apparent paradox of antimicrobial activity of spiramycin. Antibiot Annu. 1958;6:211–220. [PubMed] [Google Scholar]
- CHABBERT Y., BOYER F., SAVIARD M., BOULINGRE H., HERVE J. Détermination de l'action bactéricide in vivo des antibiotiques dans la staphylococcie rénale de la souris. Ann Inst Pasteur (Paris) 1957 Jun;92(6):760–777. [PubMed] [Google Scholar]
- CHABBERT Y. Etudes in vitro sur la spiramycine; activité, résistance, antibiogramme, concentrations humorales. Ann Inst Pasteur (Paris) 1955 Oct;89(4):434–446. [PubMed] [Google Scholar]
- COSAR C. Etude de la toxicité aiguë de la spiramycine chez la souris et de son activité sur les infections expérimentales de cet animal. Therapie. 1956;11(2):324–328. [PubMed] [Google Scholar]
- FINLAND M., JONES W. F., Jr, NICHOLS R. L. Development of resistance and cross-resistance in vitro to erythromycin, carbomycin, spiramycin, oleandomycin and streptogramin. Proc Soc Exp Biol Med. 1956 Nov;93(2):388–393. doi: 10.3181/00379727-93-22766. [DOI] [PubMed] [Google Scholar]
- GARROD L. P. The erythromycin group of antibiotics. Br Med J. 1957 Jul 13;2(5036):57–63. doi: 10.1136/bmj.2.5036.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GARROD L. P., WATERWORTH P. M. Behaviour in vitro of some new antistaphylococcal antibiotics. Br Med J. 1956 Jul 14;2(4984):61–65. doi: 10.1136/bmj.2.4984.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- JONES W. F., Jr, FINLAND M. Antibiotic combinations; tetracycline, erythromycin, oleandomycin and spiramycin, and combinations of tetracycline with each of the other three agents; comparisons of activity in vitro and antibacterial action of blood after oral administration. N Engl J Med. 1957 Sep 12;257(11):481–contd. doi: 10.1056/NEJM195709122571101. [DOI] [PubMed] [Google Scholar]
- LOWBURY E. J., HURST L. The sensitivity of staphylococci and other wound bacteria to erythromycin, oleandomycin, and spiramycin. J Clin Pathol. 1959 Mar;12(2):163–169. doi: 10.1136/jcp.12.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- MANIAR A. C., EIDUS L., GREENBERG L. A comparison of the in vitro and in vivo activity of erythromycin and spiramycin. Antibiot Chemother (Northfield) 1960 Dec;10:726–730. [PubMed] [Google Scholar]